Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in mutated NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459558 | PMC |
| http://dx.doi.org/10.1159/000525341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer.
Drug Dev Res
September 2025
R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India.
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with "epidermal growth factor receptor (EGFR)" mutations playing a pivotal role in tumor progression and carcinogenesis. "Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs)," such as Osimertinib, have significantly improved treatment outcomes by overcoming resistance mechanisms like the T790M mutation. However, Osimertinib's clinical application is limited by cardiotoxicity concerns, necessitating safer alternatives.
View Article and Find Full Text PDFPrognostic factors, patterns of failure and re-irradiation in hypofractionated stereotactic radiotherapy-treated brain metastases from non-small cell lung cancer.
Clin Transl Radiat Oncol
November 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Background: Hypofractionated stereotactic radiotherapy (fSRT) is increasingly used for brain metastases (BMs) from non-small cell lung cancer (NSCLC). However, relevant data concerning treatment outcomes of fSRT and clinical utility of re-irradiation using fSRT (re-fSRT) remain scarce.
Methods: Consecutive NSCLC patients with fSRT-treated BMs from May 2018 to May 2022 were included.
Effects of Moving the Irradiation Isocenter From the Lesion to the Center of the Brain on High-Definition Dynamic Radiosurgery Planning With Volumetric-Modulated Arcs for Single Brain Metastases.
Cureus
August 2025
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Background This study was conducted to examine the effects of moving the isocenter (IC) position from the lesion to the center of the brain on stereotactic radiosurgery (SRS) planning with volumetric-modulated arcs (VMA) using the High-Definition Dynamic Radiosurgery (HDRS) platform, a combination of the Agility multileaf collimator (MLC) (Elekta AB, Stockholm, Sweden) and the Monaco planning system (Elekta AB), for single brain metastases (BMs). Methodology The study subject included 36 clinical BMs with the gross tumor volume (GTV) ranging from 0.04 to 48.
View Article and Find Full Text PDFSignificance of Inverse Planning With Variable Dose Rate and the Segment Shape Optimization in Dynamic Conformal Arcs Using the High-Definition Dynamic Radiosurgery Platform for Single Brain Metastases.
Cureus
August 2025
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Purpose This planning study aimed to clarify the significance of inverse planning with variable dose rate (VDR) and the segment shape optimization (SSO) in the quality and efficiency of dynamic conformal arcs (DCA) using the high-definition dynamic radiosurgery (HDRS) platform for stereotactic radiosurgery (SRS) of single brain metastases (BMs). Materials and methods Twenty clinical BMs were included, with the gross tumor volume (GTV) ranging from 0.33 cc to 48.
View Article and Find Full Text PDFCase Report: Abscopal effect and long-term survival in a PD-L1 negative NSCLC patient treated with radiotherapy and immuno-chemotherapy.
Front Immunol
September 2025
Department of Radiation Oncology, Jiangxi Cancer Hospital and Institute, Jiangxi Clinical Research Center for Cancer, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
We present a case of a 68-year-old male with advanced non-small cell lung cancer (NSCLC), PD-L1 negative and driver gene negative, who exhibited a significant abscopal effect following radiotherapy combined with systemic immunotherapy (sintilizumab) and chemotherapy. The patient achieved complete remission (CR) of intracranial metastases without cranial irradiation, suggesting a systemic immune response triggered by the combination of radiotherapy and immunotherapy. This case highlights the potential of radiotherapy combined with immuno-chemotherapy to induce abscopal effects, even in PD-L1 negative patients, and underscores the importance of further investigation into this therapeutic strategy.
View Article and Find Full Text PDF